Recent advances in the discovery of senolytics

Mech Ageing Dev. 2021 Dec:200:111587. doi: 10.1016/j.mad.2021.111587. Epub 2021 Oct 14.

Abstract

The demonstration in model organisms that cellular senescence drives aging and age-related diseases has led to widespread efforts to identify compounds able to selectively kill senescent cells, termed senolytics. Approaches used to identify senolytics include bioinformatic analysis of senescent cell anti-apoptotic pathways (SCAPs) for drug development and screening of drugs libraries on different senescent cell types in culture. Alternatively, cytotoxic compounds can be made specific to senescent cells through a prodrug strategy such as linking the compound to a galactose moiety where toxicity is activated by lysosomal β-galactosidase. Identified senolytics can then be optimized through medicinal chemistry or linking to E3 targeting moieties to facilitate proteolysis of their targets. This review will provide an overview of approaches to identify senolytics and an update of the classes of senolytics identified to date.

Keywords: Aging; Drug screening; PROTACs; Prodrugs; Senescence; Senolytics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cellular Senescence* / drug effects
  • Cellular Senescence* / physiology
  • Drug Development / methods*
  • Drug Discovery* / methods
  • Drug Discovery* / trends
  • Humans
  • Longevity / drug effects
  • Senotherapeutics / pharmacology*

Substances

  • Senotherapeutics